Post by Aenova Group

💊 De-risking Modified Release: Why Pellets Deserve a Closer Look There are many ways to achieve modified release – but pellet-based systems offer a compelling mix of flexibility, patient-centric dosing and life-cycle options. The challenge is turning a lab concept into a robust commercial process. Our whitepaper “Mastering Modified Release with Pellets – From Lab to Line” shows how an integrated GMP site with development, analytics and manufacturing can: ▪️ de-risk tech transfer of modified release pellets ▪️ shorten scale-up timelines using real manufacturing data ▪️ improve confidence in CDMO selection and outsourcing decisions 📄 Access the white paper: https://lnkd.in/dfFHcDBN #Aenova #CDMO #ModifiedRelease #Pellets #DrugDelivery #PharmaOutsourcing